Phase 3 data support “changing the current standard of care to now include neoadjuvant and adjuvant pembrolizumab,” according to Ravindra Uppaluri, MD, PhD.

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improves event-free survival.

Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54% Strong efficacy signal observed in non-squamous ...

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating ...

The FDA clears GL-IL2-138, a groundbreaking oral drug modulating natural IL-2, set to revolutionize treatment in oncology.

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.

Pfizer (PFE), a global pharmaceutical giant that was once a pandemic darling, is now facing turbulence. Following a period of extraordinary vaccine-driven revenue, the company now faces a more ...

As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing ...